Assessment of pharmacogenetic tests: Presenting measures of clinical validity and potential population impact in association studies

E. C.M. Tonk, D. Gurwitz, A. H. Maitland-Van Der Zee, A. C.J.W. Janssens

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The progressing discovery of genetic variants associated with drug-related adverse events has raised expectations for pharmacogenetic tests to improve drug efficacy and safety. To further the use of pharmacogenetics in health care, tests with sufficient potential to improve efficacy and safety, as reflected by good clinical validity and population impact, need to be identified. The potential benefit of pharmacogenetic tests is often concluded from the strength of the association between the variant and the adverse event; measures of clinical validity are generally not reported. This paper describes measures of clinical validity and potential population health impact that can be calculated from association studies. We explain how these measures are influenced by the strength of the association and by the frequencies of the variant and the adverse event. The measures are illustrated using examples of testing for HLA-B∗5701 associated with abacavir-induced hypersensitivity and SLCO1B1 c.521T>C (∗5) associated with simvastatin-induced adverse events.

Original languageEnglish
Pages (from-to)386-392
Number of pages7
JournalPharmacogenomics Journal
Volume17
Issue number4
DOIs
Publication statusPublished - 1 Jul 2017

Cite this

Tonk, E. C.M. ; Gurwitz, D. ; Maitland-Van Der Zee, A. H. ; Janssens, A. C.J.W. / Assessment of pharmacogenetic tests : Presenting measures of clinical validity and potential population impact in association studies. In: Pharmacogenomics Journal. 2017 ; Vol. 17, No. 4. pp. 386-392.
@article{6574122f686f4acb8d3c419c1b2f6ba1,
title = "Assessment of pharmacogenetic tests: Presenting measures of clinical validity and potential population impact in association studies",
abstract = "The progressing discovery of genetic variants associated with drug-related adverse events has raised expectations for pharmacogenetic tests to improve drug efficacy and safety. To further the use of pharmacogenetics in health care, tests with sufficient potential to improve efficacy and safety, as reflected by good clinical validity and population impact, need to be identified. The potential benefit of pharmacogenetic tests is often concluded from the strength of the association between the variant and the adverse event; measures of clinical validity are generally not reported. This paper describes measures of clinical validity and potential population health impact that can be calculated from association studies. We explain how these measures are influenced by the strength of the association and by the frequencies of the variant and the adverse event. The measures are illustrated using examples of testing for HLA-B∗5701 associated with abacavir-induced hypersensitivity and SLCO1B1 c.521T>C (∗5) associated with simvastatin-induced adverse events.",
author = "Tonk, {E. C.M.} and D. Gurwitz and {Maitland-Van Der Zee}, {A. H.} and Janssens, {A. C.J.W.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1038/tpj.2016.34",
language = "English",
volume = "17",
pages = "386--392",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "4",

}

Assessment of pharmacogenetic tests : Presenting measures of clinical validity and potential population impact in association studies. / Tonk, E. C.M.; Gurwitz, D.; Maitland-Van Der Zee, A. H.; Janssens, A. C.J.W.

In: Pharmacogenomics Journal, Vol. 17, No. 4, 01.07.2017, p. 386-392.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Assessment of pharmacogenetic tests

T2 - Presenting measures of clinical validity and potential population impact in association studies

AU - Tonk, E. C.M.

AU - Gurwitz, D.

AU - Maitland-Van Der Zee, A. H.

AU - Janssens, A. C.J.W.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - The progressing discovery of genetic variants associated with drug-related adverse events has raised expectations for pharmacogenetic tests to improve drug efficacy and safety. To further the use of pharmacogenetics in health care, tests with sufficient potential to improve efficacy and safety, as reflected by good clinical validity and population impact, need to be identified. The potential benefit of pharmacogenetic tests is often concluded from the strength of the association between the variant and the adverse event; measures of clinical validity are generally not reported. This paper describes measures of clinical validity and potential population health impact that can be calculated from association studies. We explain how these measures are influenced by the strength of the association and by the frequencies of the variant and the adverse event. The measures are illustrated using examples of testing for HLA-B∗5701 associated with abacavir-induced hypersensitivity and SLCO1B1 c.521T>C (∗5) associated with simvastatin-induced adverse events.

AB - The progressing discovery of genetic variants associated with drug-related adverse events has raised expectations for pharmacogenetic tests to improve drug efficacy and safety. To further the use of pharmacogenetics in health care, tests with sufficient potential to improve efficacy and safety, as reflected by good clinical validity and population impact, need to be identified. The potential benefit of pharmacogenetic tests is often concluded from the strength of the association between the variant and the adverse event; measures of clinical validity are generally not reported. This paper describes measures of clinical validity and potential population health impact that can be calculated from association studies. We explain how these measures are influenced by the strength of the association and by the frequencies of the variant and the adverse event. The measures are illustrated using examples of testing for HLA-B∗5701 associated with abacavir-induced hypersensitivity and SLCO1B1 c.521T>C (∗5) associated with simvastatin-induced adverse events.

UR - http://www.scopus.com/inward/record.url?scp=84966658548&partnerID=8YFLogxK

U2 - 10.1038/tpj.2016.34

DO - 10.1038/tpj.2016.34

M3 - Article

VL - 17

SP - 386

EP - 392

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 4

ER -